Latest Breaking News On - Katie abouzahr - Page 1 : comparemela.com

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

Katie Abouzahr, MD, explains the transformative potential of nipocalimab for the treatment of patients with autoantibody-driven conditions.

Katie-abouzahr
Johnson-katie-abouzahr
Johnson
Drug-administration
Fast-track
Maternal-fetal-immunology-disease-area-leader

J&J targets rare maternal-fetal disease: 'We're going for this.'

J&J targets rare maternal-fetal disease: 'We're going for this.'
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Argenx-vyvgart
Katie-abouzahr
Momenta-pharmaceuticals
Johnson
Big-pharma
New-jersey-based

FDA Grants Fast Track Designation to Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia

In December 2023, nipocalimab (Johnson & Johnson) was granted orphan drug designation for fetal neonatal alloimmune thrombocytopenia.

Jacob-lund
Katie-abouzahr
Johnson
Janssen-research-development
Maternal-fetal-immunology-disease-area-leader
Severe-hemolytic-disease
Janssen-research
Breakthrough-therapy-designation
Rare-disease

J&J's growing rare disease focus brings a potential multi-use treatment to the table

BioPharma

Katie-abouzahr
Johnson
Big-pharma
Pharma

The FDA has Approved a breakthrough therapy designation for Johnson & Johnson's Nipocalimab

#industry #news #UK #2024 #insights #zenopa #recruitment #pharmaceuticals #FDA #breakthrough #therapy #designation for #Johnson&Johnson #Nipocalimab

Katie-abouzahr
Johnson